NCT05046470|Unknown
SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological Pilot Study
DYNAtracs
Loading search results
DYNAtracs
Sponsor study identifier
Secondary identifiers
REGISTRY · ISRCTN registry
observational
1,233
1 country
1
Study Start
January 14, 2021
Actual (reported)Primary Completion
January 14, 2023
Actual (reported)Study Completion
January 14, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The investigators hypothesize that children are less likely to become infected in the school environment, compared to the household or outside the school setting. Primary schools do not play a major role in SARS-CoV-2 spreading. They hypothesize that incidence level in schools is mainly a consequence of community transmission. The incidence level in household and that the secondary attack rate in schools remains at least 5 times lower that the transmission level in households.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 14, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 14, 2021
Actual (reported)September 7, 2021
Actual (reported)September 16, 2021
Actual (reported)January 14, 2023
Actual (reported)January 14, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Infection of a child with SARS-CoV-2 secondary to a classmate
Time varying number and proportion of children infected with SARS-CoV-2 secondary to an asymptomatic infected classmate (transmission rate inside school with the child being the infector).
6 weeks
Infection of an adult school-attender with SARS-CoV-2 secondary to an infected child
Time varying number and proportion of adult school-attenders infected with SARS-CoV-2 secondary to an asymptomatic infected child (transmission rate inside school but from a child to an adult).
6 weeks
Infection of a child with SARS-CoV-2 secondary to an adult school attender
Time varying number and proportion of children infected with SARS-CoV-2 secondary to an infected adult school-attender (transmission rate inside school but from an adult to a child)
6 weeks
Infection of a child with SARS-CoV-2 secondary to a contact outside the school, including the household
Time varying number and proportion of children infected with SARS-CoV-2 secondary to a household contact or outside the school (transmission rate from in community).
6 weeks
All Belgian primary schools of the Federation Wallonia - Brussels that have organized a full resumption of school activities with the control measures recommended by the government, are eligible for the study. Twelve schools were chosen by purposive criteria: either high (≥2 classes per grade) or low size of the school, a school within an area with either a high or a low incidence of SARS-CoV-2 during April 2020, the first wave of covid-19 in Belgium, and a school with either a high or a low socioeconomic level (Belgian 20-point-scale ISE idex \>14 or \<6).
UCLouvain
Brussels, 1200, Belgium
Saliva samples
Annie Robert, Pr
Université Catholique de Louvain
1,233 participants (actual enrollment reported by the registry).
First Submitted
September 7, 2021
First Posted
September 16, 2021
Study Start
January 14, 2021
Actual (reported)COVID-19 Vaccination Uptake in Belgium : Sociodemographic and Socioeconomic Disparities
Contact the study team to confirm eligibility.
Primary Completion
January 14, 2023
Actual (reported)Study Completion
January 14, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 8, 2024
Record last verified: 2024-05
All collected IPD
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: